Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II

Kim, Sung Bae; Sayeed, Ahmed; Villalon, Antonio H; Shen, Zhen Zhou; Yau, Tsz Kok; Shah, Mazhar Ali; Hou, Meng Feng; Thuan, Tran Van; Ba, Duc Nguyen; Chao, Tsu-Yi

추천

검색

자료유형: 학술저널

저자정보: Kim, Sung Bae (Asan Medical Center, University of Ulsan College of Medicine) Sayeed, Ahmed (Holy Family Red Crescent Medical College Hospital) Villalon, Antonio H (Manila Doctors Hospital) Shen, Zhen Zhou (Shanghai Fudan University Cancer Hospital) Yau, Tsz Kok (Pamela Youde Nethersole Eastern Hospital) Shah, Mazhar Ali (Shaukat Khanum Memorial Cancer Hospital and Research Centre) Hou, Meng Feng (Kaohsiung Medical University) Thuan, Tran Van (K Institute [National Cancer Hospital]) Ba, Duc Nguyen (National Cancer Hospital) Chao, Tsu-Yi (Tri-Service General Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제17권 제2호

발행연도: 2016.1

수록면: 697 - 702 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The Asia-Pacific Breast Initiatives (APBI) I and II registries were established to collect safety data for patients with early stage breast cancer receiving adjuvant docetaxel-based regimens in the Asia-Pacific region. Materials and Methods: Data from the two registries were combined to perform a safety analysis. Participants in the registry were women with early stage operable breast cancer with an intermediate or high risk of recurrence. These women received adjuvant chemotherapy that included docetaxel between 2006 and 2011. Adverse events (AEs) were recorded and analyzed. Results: Data were collected from 3,224 patients from 13 countries. The mean dose intensity of docetaxel was 24.1, 22.7, $25.1mg/m^2/week$ among patients receiving docetaxel-based monotherapy, combination therapy and sequential therapy, respectively. Granulocyte colony-stimulating factor (G-CSF) was given with docetaxel to 41.8% of women and 20.6% of women receiving prophylactic antibiotics. Adverse events were reported in 86% of patients (anthracycline-containing regimens vs. non-anthracycline regimens; 87% vs. 80%). The most common adverse events were alopecia, nausea, neutropenia, vomiting, and myalgia. Adverse events NCI CTCAE ${\geq}$Grade 3 were reported in 45.4% of patients. Serious adverse events were reported in 13% of patients, of which 2.5% led to study discontinuation. Forty-six deaths (1.4%) were reported, with no significant difference between regimens. Conclusions: The safety parameters of adjuvant docetaxel therapy used to treat sequential Asian women were comparable to those reported in clinical trials evaluating the role of adjuvant docetaxel. No unusual adverse events linked to Asia-Pacific region patients were observed.

#Adjuvant therapy #docetaxel #early breast cancer #taxanes

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!